Company profile for WindMIL Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At WindMIL Therapeutics®, we are dedicated to our mission: Translating novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The bone marrow has an important role in the immune system, acting as a reservoir of persistent immune cells generated as a response to foreign antigens. Our proprietary process creates a cellular product called MILs™ (Marrow Infiltrating Lymphocytes) that conta...
At WindMIL Therapeutics®, we are dedicated to our mission: Translating novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The bone marrow has an important role in the immune system, acting as a reservoir of persistent immune cells generated as a response to foreign antigens. Our proprietary process creates a cellular product called MILs™ (Marrow Infiltrating Lymphocytes) that contains these activated tumor-targeting memory T cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1812 Ashland Avenue, Suite 100 Baltimore, MD 21205
Telephone
Telephone
(410) 558-1906
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2020/11/09/2122688/0/en/WindMIL-Therapeutics-Presents-New-Marrow-Infiltrating-Lymphocytes-MILs-Data-Demonstrating-Broad-Therapeutic-Promise-for-Solid-Tumor-Cancers.html

GLOBENEWSWIRE
09 Nov 2020

https://www.globenewswire.com/news-release/2020/04/21/2019178/0/en/WindMIL-Therapeutics-Opens-Combination-Therapy-Portion-of-its-Phase-2a-Clinical-Trial-of-Marrow-Infiltrating-Lymphocytes-MILs-for-Treatment-of-Patients-with-Non-Small-Cell-Lung-Can.html

GLOBENEWSWIRE
21 Apr 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty